Evidence map›Paper›PMID 37592966›Full record

ArticleAntimicrobial stewardship & healthcare epidemiology : ASHE2023

Antibiotic Selection and Duration for Catheter-Associated Urinary Tract Infection in Non-Hospitalized Older Adults: A Population-Based Cohort Study.

Bradley J Langford, Nick Daneman, Christina Diong, Samantha M Lee, Daniel J Fridman, Jennie Johnstone, Derek MacFadden, Kwadwo Mponponsuo, Samir N Patel, Kevin L Schwartz and 1 more

Open access · goldAbstract read
In one paragraph

Article in Antimicrobial stewardship & healthcare epidemiology : ASHE, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. CAUTIon - not all UTIs are the same.Nature reviews. Urology · 2025
    Review
  3. Role of Clot Formation and Plasminogen Activation in Lower Urinary Tract Pathologies.Arteriosclerosis, thrombosis, and vascular biology · 2025
    Review
  4. Article
  5. Antimicrobial Functionalization of Silicone-graft-poly(Molecules (Basel, Switzerland) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Bradley J Langford *Public Health Ontario, Toronto, Canada.ORCID https://orcid.org/0000-0001-5467-6776
Nick DanemanPublic Health Ontario, Toronto, Canada.
Christina DiongICES, Toronto, Canada.
Samantha M LeeICES, Toronto, Canada.ORCID https://orcid.org/0000-0003-1162-8744
Daniel J FridmanICES, Toronto, Canada.ORCID https://orcid.org/0000-0002-2516-9967
Jennie JohnstonePublic Health Ontario, Toronto, Canada.
Derek MacFaddenOttawa Hospital Research Institute, Ottawa, Ontario, Canada.
Kwadwo MponponsuoICES, Toronto, Canada.ORCID https://orcid.org/0000-0001-8228-9095
Samir N PatelPublic Health Ontario, Toronto, Canada.
Kevin L SchwartzPublic Health Ontario, Toronto, Canada.
Kevin A BrownPublic Health Ontario, Toronto, Canada.
University of Toronto · CAInstitute for Clinical Evaluative Sciences · CAOttawa Hospital · CASunnybrook Health Science Centre · CAUniversity of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: We sought to evaluate the impact of antibiotic selection and duration of therapy on treatment failure in older adults with catheter-associated urinary tract infection (CA-UTI). Methods: We conducted a population-based cohort study comparing antibiotic treatment options and duration of therapy for non-hospitalized adults aged 66 and older with presumed CA-UTI (defined as an antibiotic prescription and an organism identified in urine culture in a patient with urinary catheterization documented within the prior 90 d). The primary outcome was treatment failure, a composite of repeat urinary antibiotic prescribing, positive blood culture with the same organism, all-cause hospitalization or mortality, within 60 days. We determined the risk of treatment failure accounting for age, sex, comorbidities, and healthcare exposure using log-binomial regression. Results: Of 4,436 CA-UTI patients, 2,709 (61.1%) experienced treatment failure. Compared to a reference of TMP-SMX (61.9% failure), of those treated with fluoroquinolones, 56.3% experienced failure (RR 0.91, 95% CI: 0.85-0.98) and 60.9% of patients treated with nitrofurantoin experienced failure (RR 1.02, 95% CI: 0.94-1.10). Compared to 5-7 days of therapy (treatment failure: 59.4%), 1-4 days was associated with 69.5% failure (RR 1.15, 95% CI: 1.05-1.27), and 8-14 days was associated with a 62.0% failure (RR 1.05, 95% CI: 0.99-1.11). Conclusions: Although most treatment options for CA-UTI have a similar risk of treatment failure, fluoroquinolones, and treatment durations ≥ 5 days in duration appear to be associated with modestly improved clinical outcomes. From a duration of therapy perspective, this study provides reassurance that relatively short courses of 5-7 days may be reasonable for CA-UTI.

Identifiers

PMID37592966
PMCPMC10428148
OpenAlexW4385447408

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.